Georgia is a rapidly developing country at the intersection of Eastern Europe and Western Asia. It has a population of 3.7 million people. Many local and global companies conduct clinical research in Georgia due to numerous advantages the country has to offer: full compliance with GCP, clear regulatory requirements and a simplified process of document submission, high quality of data, and acceptance by EMA and FDA.
On the 20th of July 2022, the Resolution of the Government of Georgia was updated. It entered into force on the 5th of August 2022. According to the amendment, 70% of the fee for the registration certificate to the permit certificate for the clinical trial of a pharmacological agent (I-IV Phase) will be returned in case of refusal by the authorities.
Georgia has an ethnically diverse population and a significant number of treatment naïve patients in a range of therapeutic areas, well-educated clinical staff with experience in GCP, and most hospitals are very interested to participate in clinical trials.